Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Articles tagged with "AC&R"

The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights

  |  

CHICAGO—Stem cell transplantation for systemic sclerosis patients has come a long way over the past decade, with more finely calibrated dosing and better patient selection, said George Georges, MD, associate member of the Fred Hutchinson Cancer Research Center and associate professor in the medical oncology division at the University of Washington School of Medicine, Seattle,…

The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy

  |  

CHICAGO—Scleroderma patients with pulmonary arterial hypertension (PAH) might benefit from more aggressive therapy, an expert in the field said in a session on lung involvement in rheumatic diseases at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May. Newer trials—the SERAPHIN trial on macitentan, GRIPHON on selexipag, and AMBITION on an ambrisentan/tadalafil combination—show…

The ACR’s State-of-the-Art Clinical Symposium: Rheumatic, Malignant Disease Mimics Call for Diligence from Rheumatologists

  |  

CHICAGO—David Daikh, MD, PhD, professor of medicine at the University of California San Francisco and chief of the Rheumatology Division at the San Francisco VA Medical Center, said the overlap between malignant disease and rheumatic disease means rheumatologists should stay aware that more may be going on than just a rheumatic disorder. He made his…

The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis

  |  

CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…

The ACR Partners with Coalition, Patient Advocacy Groups to Advocate for Rheumatology

Chris Morris, MD, RheumPAC Committee  |  

In terms of getting our message heard in Washington, D.C., rheumatology faces a David vs. Goliath battle on several levels. Many industries have far greater resources, use multiple lobbying firms, and have advertising and lobbying budgets that eclipse ours by several hundred-fold. Rheumatology is far smaller than most other medical specialties; our membership is a…

Rheumatologist Shares ACR State-of-the-Art Clinical Symposium Experience

Wambui Machua, MD, BS  |  

The annual ACR State-of-the-Art (SOTA) Clinical Symposium came highly endorsed by previous fellows; therefore, upon receiving the invitation for the Fellows-in-Training (FIT) scholarship, I did not hesitate to apply. Further, the meeting was going to be held in the spring in Chi Town! Meticulously, I made arrangements with six hundred scholarship dollars at my disposal….